Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Noboru YamamotoTakafumi KoyamaJun SatoTatsuya YoshidaKazuki SudoSatoru IwasaShunsuke KondoKan YonemoriAtsuko KawasakiKyoko SatakeShoyo ShibataToshio ShimizuPublished in: Cancer chemotherapy and pharmacology (2024)
jRCT2080224926.